// App-Quantinova.ai

1034 : Addition of carboplatin to standard chemotherapy in the adjuvant treatment of unselected triple negative breast cancers (TNBC).

Researchers

Presenter

  • Marcus Vetter

Principal Investigators

  • Spyridon Fokas

  • Ewelina Biskup

  • Thomas Schmid

  • Fabienne Schwab

  • Andreas Schoetzau

  • Uwe Gueth

  • Christoph Rochlitz

  • Rosanna Zanetti-Daellenbach

Medical Centers

  • Universitaetsspital, Basel, Switzerland

  • University Hospital Basel, Basel, Switzerland

  • The Royal Marsden Hospital, London, United Kingdom

  • Brust Zentrum Zurich, Zurich, Switzerland

Locations

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Triple-negative breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Carboplatin

  • taxane

Outcome

  • N/A

Study Design

  • Cohort

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved